-
1 week ago | 
pharmaceuticalcommerce.com | Don Tracy
Bringing Biotech Innovation Across BordersA feature published by Pharmaceutical Executive authored by Ed Ahn, CEO of MEDIPOST, Inc, outlines four tips for midsized companies when entering new global markets.
-
1 week ago | 
pharmaceuticalcommerce.com | Don Tracy
The FDA has granted interchangeability designation to Celltrion’s Yuflyma (adalimumab-aaty), a high-concentration (100 mg/mL), citrate-free biosimilar of Humira (adalimumab), across multiple inflammatory indications.
-
1 week ago | 
pharmaceuticalcommerce.com | Don Tracy
Pharma companies expected to absorb any tariff hit in short termWhile US tariffs on pharmaceuticals may eventually raise drug prices, especially for generics, experts say brand-name costs will likely be absorbed by manufacturers in the short term—impacting profits, research, and staffing—while the broader goal may be to pressure companies into narrowing the price gap between the US and other countries.
-
2 weeks ago | 
pharmaceuticalcommerce.com | Don Tracy
PC: What general advice do you have for other pharma supply chain stakeholders when it comes to delivering change that boosts growth, augments pipelines, and increases productivity? Lang: First of all, I think there needs to be alignment and a clear understanding at the executive level that operations is a strategic enabler. For the past 10 to 20 years, operations have often been viewed as a tactical function.
-
2 weeks ago | 
pharmaceuticalcommerce.com | Don Tracy
PC: As the co-chair of this year’s conference, are there any sessions that have stood out to you the most? Hagan: There have been really strong sessions overall, especially today as we kicked off the conference. I’d say that more than individual sessions, it’s the recurring themes that stand out as especially important.
-
2 weeks ago | 
pharmaceuticalcommerce.com | Don Tracy
Boehringer Ingelheim announced the official opening of a new antibody-drug conjugate (ADC) research and development facility in Basel, Switzerland, through its wholly owned subsidiary, NBE Therapeutics.
-
2 weeks ago | 
appliedclinicaltrialsonline.com | Don Tracy
One-year data from the SmartfIRE trial show that Johnson & Johnson’s (J&J) dual energy Thermocool Smarttouch SF catheter demonstrated high efficacy in treating drug-refractory symptomatic paroxysmal atrial fibrillation (AFib).
-
3 weeks ago | 
pharmaceuticalcommerce.com | Don Tracy
PC: What are some of the biggest challenges in ensuring continued medication adherence for specialty patients? Butler: While technology and high-touch support are important, personalization is equally critical. Emotions fluctuate daily, and medication regimens, as well as chronic conditions, evolve over time. Whenever we implement a solution, we must continuously check in to ensure patients remain on track and feel confident in taking the next step.
-
3 weeks ago | 
pharmaceuticalcommerce.com | Nicholas Saraceno |Don Tracy
In this exclusive PC Podcast interview, Renier Brentjens, MD, PhD, deputy director and chair of medicine at the Roswell Park Comprehensive Cancer Center, discusses: How he has seen the field evolve since its inception, and what excites him most about its future How the Roswell Park expansion helps improve patient access to CAR T-cell therapy The key safety concerns associated with CAR T-cell therapy, along with how Roswell Park aims to mitigate potential risks How Roswell Park is working to...
-
3 weeks ago | 
pharmaceuticalcommerce.com | Don Tracy
PC: How is the role of patient engagement evolving in specialty pharmacy? Butler: It’s becoming increasingly critical to evolve patient support in specialty pharmacy, as patients now expect more personalized care. With the rapid advancement of technology, they also anticipate greater connectivity. While access to information is beneficial, it can also be overwhelming.
